4’-hydroxy Tamoxifen – 1 mg

Brand:
Cayman
CAS:
82413-23-8
Storage:
-20
UN-No:
Non-Hazardous - /

4’-hydroxy Tamoxifen is one of five main phase I metabolites of tamoxifen (Item No. 13258), a well-known estrogen receptor antagonist in breast but partial estrogen receptor agonist in endometrium. 4’-hydroxy Tamoxifen is a product of cytochrome P450 (CYP)2D6 and CYP2B6 activity.{31466,28446,31468} With the addition of a hydroxyl group, 4’-hydroxy tamoxifen has been shown to have a higher affinity for estrogen receptors compared to tamoxifen.{31469} At 10-100 µM, 4’-hydroxy tamoxifen is cytotoxic, in a non-apoptotic manner, to HEC-1B and HEC-1A human endometrial adenocarcinoma cell lines.{31467}  

 

Available on backorder

SKU: - Category:

Description

A metabolite of tamoxifen that has been shown to have a higher affinity for estrogen receptors compared to tamoxifen; demonstrates non-apoptotic cytotoxicity in HEC-1B and HEC-1A human endometrial adenocarcinoma cell lines


Formal name: 4-[(1Z)-1-[[4-[2-(dimethylamino)ethoxy]phenyl]phenylmethylene]propyl]-phenol

Synonyms: 

Molecular weight: 387.5

CAS: 82413-23-8

Purity: ≥98% (may contain up to 10% of the (E) isomer)

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Product Type|Biochemicals|Xenobiotic Metabolites||Research Area|Cancer|Cell Death||Research Area|Endocrinology & Metabolism|Hormones & Receptors|Estrogens & Progestins||Research Area|Toxicology|Drug Metabolism|Cytochrome P450||Research Area|Toxicology|Drug Metabolism|Drug Metabolites